A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy caregiver challenges and referral ...

PRINCETON, N.J.-- (BUSINESS WIRE)--Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025 ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the best stocks to buy for beginners now. On June 12, Bristol Myers Squibb ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the best stocks to buy for beginners now. On June 12, Bristol Myers Squibb ...

BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. ARV-393 demonstrated significant single-agent activity in a patient derived xenograft (PDX) model of nodal ...

The BCL6 protein facilitates B cell tolerance of rapid proliferation and somatic gene recombination via repressing cell cycle checkpoints, terminal differentiation, apoptosis, and the DNA damage ...

Bristol Myers Squibb presents data across targeted protein degradation research including CELMoD agents and BCL6 ligand-directed degrader at EHA 2025: Princeton, New Jersey Friday ...

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced ...

– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma ...